Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Inhibrx's INBRX-101?
INBRX-101 is a fusion protein commercialized by Inhibrx, with a leading Phase II program in Emphysema. According to Globaldata, it...
Data Insights
Risk adjusted net present value: What is the current valuation of Sanofi's INBRX-101?
INBRX-101 is a fusion protein commercialized by Sanofi, with a leading Phase II program in Emphysema. According to Globaldata, it...